Marc Bernstein, MD
Cardiovascular Disease · Slidell, LANPI 1851333587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 909 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 909 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pfizer$1K
- Johnson & Johnson$1K
- Acarix USA Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Medtronic$972
- plus $8K from 49 others
Across 645 payments — averaging $3363.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$657K
- Novartis$490K
- Novo Nordisk AS$410K
- Eli Lilly$192K
- Janssen Research & Development, LLC$191K
- Boehringer Ingelheim International GmbH$80K
- plus $151K from 5 others
What the payments were for
- Speaking & faculty fees$1,2007%
- Food & beverage$14,62991%
- Education$2542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CADScor System$1,200
- CoreValve Evolut$147
- FARXIGA$144
- IGT D Coronary$115
- V-GO$110
- (6586) Pioneer$105
- (6585) Omniwire$102
How this compares
$16,083 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 773 | $731,255 |
| MounjaroTirzepatide | 309 | $395,073 |
| EntrestoSacubitril/Valsartan | 350 | $339,688 |
| OzempicSemaglutide | 190 | $240,093 |
| Repatha SureclickEvolocumab | 306 | $220,286 |
| XareltoRivaroxaban | 251 | $219,100 |
| JardianceEmpagliflozin | 132 | $141,413 |
| FarxigaDapagliflozin Propanediol | 125 | $106,954 |
| VascepaIcosapent Ethyl | 109 | $60,644 |
| NexlizetBempedoic Acid/Ezetimibe | 113 | $56,377 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $34,925 |
| BrilintaTicagrelor | 56 | $31,964 |
| MultaqDronedarone Hcl | 30 | $25,779 |
| WegovySemaglutide | 16 | $23,176 |
| TrulicityDulaglutide | 13 | $22,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,330 | $731,255773 claims |
| Lilly USA, LLCMounjaro, Trulicity | $371 | $417,248322 claims |
| NovartisEntresto | $2,063 | $339,688350 claims |
| Novo NordiskOzempic, Wegovy | $373 | $263,269206 claims |
| Johnson & JohnsonXarelto | $1,218 | $219,100251 claims |
| Boehringer IngelheimJardiance | $496 | $141,413132 claims |
| AstraZenecaFarxiga, Brilinta | $921 | $138,918181 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $410 | $72,102142 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $96 | $44,52151 claims |
| Sanofi-aventis U.S. LLCMultaq | $398 | $25,77930 claims |
| AmgenCorlanor | $768 | $13,67124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Slidell
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
- Darrell SoletMorgan City$81K
- Ghiath MikdadiHammond$76K
- Samuel StaggHouma$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.